Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

ZPZhigang PengKDKaiyang DingJWJianqiu Wu

Discussion

Loading...

Member takes

Overview

A Phase II trial found rocbrutinib resulted in improved progression-free survival in patients with relapsed mantle cell lymphoma, suggesting potential clinical impact.

Key Points

  • Rocbrutinib led to a promising progression-free survival in relapsed mantle cell lymphoma patients, demonstrating efficacy.
  • The overall response rate observed was 63.9%, highlighting the treatment's potential in a difficult-to-treat population.
  • Assessment from a multicenter phase II trial showed the manageable safety profile with a low incidence of adverse events.
  • These results indicate that rocbrutinib may serve as a new option for patients previously treated with BTK inhibitors.

Cite This Study

Peng et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d96fhttps://doi.org/10.1182/blood-2025-886
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study2025
  2. 2Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)2025 · 3 citations
  3. 3Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor2025 · 2 citations
  4. 4Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study2025 · 6 citations
  5. 5Preliminary efficacy and safety of TT-01488, a novel, non-covalent, reversible BTK inhibitor, in patients with relapsed/refractory mantle cell lymphoma2025